Kenvue: B of A Securities maintains a 'Buy' Rating, The Target Price is $25
AinvestTuesday, Jul 15, 2025 12:00 pm ET

B of A Securities maintains 'Buy' rating on Kenvue(KVUE).
The target price is $25, compare with $27 previously.
[Recent Rating]
Date | Agency | Change | Rating | Rating (previously) | Target Price | Target Price(previously) |
---|---|---|---|---|---|---|
2025-07-15 | B of A Securities | Maintains | Buy | Buy | $25 | $27 |
2025-07-15 | Barclays | Maintains | Equal-Weight | Equal-Weight | $22 | $23 |
2025-07-15 | Citigroup | Maintains | Neutral | Neutral | $22 | $24.5 |
[Company Profile] Kenvue Inc. was incorporated in Delaware on February 23, 2022. The company is the world’s largest pure-play consumer health company. The company seek to deliver sustainable profitable growth through delivering science-backed innovative products, solutions and experiences centered around consumer health. With a presence in more than 165 countries worldwide and an over 135-year legacy, they are a global leader at the intersection of healthcare and consumer goods.
Sign up for free to continue reading
Unlimited access to AInvest.com and the AInvest app
Follow and interact with analysts and investors
Receive subscriber-only content and newsletters
or
By continuing, I agree to the
Market Data Terms of Service and Privacy Statement
Already have an account?
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet